Primary endpoint met, clinical benefit observed in 9 of 10 patients treated with intravenously (IV)-dosed Dexmedetomidine(Dex); no meaningful responses observed in placebo arm
[Read on via official release]
Source: US SEC
View full document:
8-K_for_BioXcel_Therapeutics_Inc_8-K-11-14-2018
